Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Lexaria Bioscience Corp. | exhibit99-1.htm |
| EX-16.1 - EXHIBIT 16.1 - Lexaria Bioscience Corp. | exhibit16-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 6, 2016
LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)
| Nevada | 000-52138 | 20-2000871 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer |
| incorporation) | Identification No.) |
| #950 – 1130 West Pender Street, Vancouver, BC | Canada | V6E 4A4 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (604) 602-1675
LEXARIA CORP.
(Former name or former address, if
changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))
| Item 4.01 | Changes in Registrant’s Certifying Accountant |
| (a) |
Previous independent registered public accounting firm | |
| (i) |
On October 6, 2016, Lexaria Bioscience Corp. (the “Company”) formally informed MNP LLP of their dismissal as the Company’s independent registered public accounting firm. | |
| (ii) |
The reports of MNP LLP on the Company’s financial statements as of and for the fiscal years ended August 31, 2015 and 2014 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principle except to indicate that there was substantial doubt about the Company’s ability to continue as a going concern. | |
| (iii) |
The Company’s board of directors and audit committee participated in and approved the decision to change independent registered public accounting firms. | |
- 2 -
| (iv) |
During the fiscal years ended August 31, 2015 and 2014 and through October 6, 2016, there have been no disagreements with MNP LLP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of MNP LLP would have caused them to make reference thereto in connection with their report on the financial statements for such years. |
||
|
| |||
| (v) |
The Company has requested that MNP LLP furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements. A copy of the letter provided by MNP LLP is filed as Exhibit 16.1 to this Form 8-K. |
||
| (b) |
New independent registered public accounting firm | ||
| (1) |
On October 6, 2016, the Company engaged Davidson & Company LLP, Chartered Professional Accountants as its new independent registered public accounting firm. During the two most recent fiscal years and through October 6, 2016, the Company had not consulted with Davidson & Company LLP, Chartered Professional Accountants regarding any of the following: | ||
| (i) |
The application of accounting principles to a specific transaction, either completed or proposed; | ||
| (ii) |
The type of audit opinion that might be rendered on the Company’s financial statements, and none of the following was provided to the Company: (a) a written report, or (b) oral advice that Davidson & Company LLP, Chartered Professional Accountants concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issue; or | ||
| (iii) |
Any matter that was subject to a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K. | ||
| Item 7.01 | Regulation FD Disclosure |
A copy of the news release dated October 6, 2016 announcing the appointment of a new auditor is filed as Exhibit 99.1 to this current report and is hereby incorporated by reference.
| Item 9.01 | Financial Statements and Exhibits |
| 16.1 | Letter from MNP LLP to the SEC |
| 99.1 | Press Release dated October 6, 2016 |
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
| /s/ Chris Bunka | |
| Chris Bunka | |
| CEO, Principal Executive Officer |
Date: October 11, 2016